SI-BONE Stock Price, News & Analysis (NASDAQ:SIBN) $17.80 -0.50 (-2.73%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$17.46▼$18.4950-Day Range$15.75▼$21.3952-Week Range$11.23▼$29.51Volume399,193 shsAverage Volume353,643 shsMarket Capitalization$720.90 millionP/E RatioN/ADividend YieldN/APrice Target$27.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability SI-BONE MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside52.6% Upside$27.17 Price TargetShort InterestHealthy2.30% of Shares Sold ShortDividend StrengthN/ASustainability-1.44Upright™ Environmental ScoreNews Sentiment0.27Based on 6 Articles This WeekInsider TradingSelling Shares$761,439 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.14) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector421st out of 957 stocksSurgical & Medical Instruments Industry44th out of 78 stocks 3.5 Analyst's Opinion Consensus RatingSI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.17, SI-BONE has a forecasted upside of 52.6% from its current price of $17.80.Amount of Analyst CoverageSI-BONE has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.30% of the outstanding shares of SI-BONE have been sold short.Short Interest Ratio / Days to CoverSI-BONE has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SI-BONE has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSI-BONE does not currently pay a dividend.Dividend GrowthSI-BONE does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSI-BONE has received a 34.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cervical implants" product. See details.Environmental SustainabilityThe Environmental Impact score for SI-BONE is -1.44. Previous Next 2.4 News and Social Media Coverage News SentimentSI-BONE has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for SI-BONE this week, compared to 1 article on an average week.MarketBeat Follows3 people have added SI-BONE to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $761,439.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of SI-BONE is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SI-BONE are expected to grow in the coming year, from ($1.14) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SI-BONE is -14.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SI-BONE is -14.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSI-BONE has a P/B Ratio of 6.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SI-BONE Stock (NASDAQ:SIBN)SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Read More SIBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SIBN Stock News HeadlinesDecember 6, 2023 | americanbankingnews.comSI-BONE (NASDAQ:SIBN) Stock Rating Reaffirmed by Needham & Company LLCDecember 5, 2023 | markets.businessinsider.comSI-Bone: Strong Fundamentals and Impending Profitability Underpin Buy RatingDecember 7, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!December 4, 2023 | benzinga.comSI-BONE Stock (NASDAQ:SIBN), Analyst Ratings, Price Targets, PredictionsNovember 30, 2023 | benzinga.comSI-BONE Stock (NASDAQ:SIBN) Dividends: History, Yield and DatesNovember 30, 2023 | finance.yahoo.comSi-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for InvestorsNovember 23, 2023 | morningstar.comSI-BONE Inc SIBNNovember 21, 2023 | finance.yahoo.comInsider Sell: President, Commercial Ops Anthony Recupero Sells 8,457 Shares of SI-BONE Inc (SIBN)December 7, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 16, 2023 | seekingalpha.comSizing Up SI-BONE After Q3 EarningsNovember 14, 2023 | finance.yahoo.comSI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023November 7, 2023 | markets.businessinsider.comCantor Fitzgerald Maintains Overweight Rating for SI-BONE: Here's What You Need To KnowNovember 7, 2023 | finance.yahoo.comSI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | msn.comSI-BONE GAAP EPS of -$0.25 beats by $0.09, revenue of $34M beats by $1.62MNovember 6, 2023 | finance.yahoo.comSI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual GuidanceNovember 6, 2023 | finance.yahoo.comSI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual GuidanceNovember 6, 2023 | finance.yahoo.comSI-BONE Inc (SIBN) Reports Record Q3 2023 Financial Results, Raises Annual GuidanceNovember 5, 2023 | finance.yahoo.comThe past three years for SI-BONE (NASDAQ:SIBN) investors has not been profitableNovember 5, 2023 | markets.businessinsider.comSI-BONE earnings preview: what Wall Street is expectingNovember 1, 2023 | finance.yahoo.comSI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023October 16, 2023 | finance.yahoo.comSI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023October 9, 2023 | finance.yahoo.comSi-Bone (SIBN) Upgraded to Buy: Here's WhySeptember 8, 2023 | finance.yahoo.comHas SiBone (SIBN) Outpaced Other Medical Stocks This Year?September 6, 2023 | finance.yahoo.comDoes Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?September 5, 2023 | finance.yahoo.comSI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System RodsAugust 31, 2023 | msn.comSI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate BuyAugust 29, 2023 | finance.yahoo.comSI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023See More Headlines Receive SIBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SIBN CUSIPN/A CIK1459839 Webwww.si-bone.com Phone(408) 207-0700FaxN/AEmployees357Year Founded2008Price Target and Rating Average Stock Price Target$27.17 High Stock Price Target$33.00 Low Stock Price Target$24.00 Potential Upside/Downside+52.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,260,000.00 Net Margins-32.98% Pretax Margin-32.98% Return on Equity-32.05% Return on Assets-22.57% Debt Debt-to-Equity Ratio0.21 Current Ratio10.89 Quick Ratio9.74 Sales & Book Value Annual Sales$106.41 million Price / Sales6.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.85 per share Price / Book6.25Miscellaneous Outstanding Shares40,500,000Free Float38,314,000Market Cap$720.90 million OptionableNot Optionable Beta1.01 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Laura A. Francis MBA (Age 56)CEO & Director Comp: $1.11MMr. Anshul Maheshwari (Age 43)Chief Financial Officer Comp: $614.25kMr. Anthony J. Recupero (Age 64)President of Commercial Operations Comp: $795.32kMr. Jeff BertoliniSenior Vice President of Operations & Information TechnologyDr. Scott A. Yerby (Age 55)Senior VP of Engineering & CTO Mr. Michael A. Pisetsky (Age 45)Chief Business & Legal Affairs Officer Ms. Aimee EinsteinVice President of People & CultureDr. Daniel Joseph Cher (Age 58)Senior Vice President of Clinical & Regulatory Affairs Dr. W. Carlton Reckling (Age 61)Chief Medical Officer & VP of Medical Affairs Mr. Nikolas F. Kerr (Age 51)Senior Vice President of Product, Strategy & Business Development More ExecutivesKey CompetitorsCryoLifeNYSE:CRYOrthoPediatricsNASDAQ:KIDSNevroNYSE:NVROTreace Medical ConceptsNASDAQ:TMCIMiMedx GroupNASDAQ:MDXGView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 31,051 shares on 12/1/2023Ownership: 1.496%Deutsche Bank AGBought 2,104 shares on 11/24/2023Ownership: 0.043%Comerica BankBought 2,205 shares on 11/21/2023Ownership: 0.005%Morgan StanleyBought 237,400 shares on 11/16/2023Ownership: 1.999%Anthony J RecuperoSold 5,461 sharesTotal: $96,605.09 ($17.69/share)View All Insider TransactionsView All Institutional Transactions SIBN Stock Analysis - Frequently Asked Questions Should I buy or sell SI-BONE stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIBN shares. View SIBN analyst ratings or view top-rated stocks. What is SI-BONE's stock price target for 2024? 5 analysts have issued 1 year price targets for SI-BONE's shares. Their SIBN share price targets range from $24.00 to $33.00. On average, they expect the company's stock price to reach $27.17 in the next twelve months. This suggests a possible upside of 52.6% from the stock's current price. View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts. How have SIBN shares performed in 2023? SI-BONE's stock was trading at $13.60 on January 1st, 2023. Since then, SIBN stock has increased by 30.9% and is now trading at $17.80. View the best growth stocks for 2023 here. When is SI-BONE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our SIBN earnings forecast. How were SI-BONE's earnings last quarter? SI-BONE, Inc. (NASDAQ:SIBN) issued its quarterly earnings results on Monday, November, 6th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.08. The company had revenue of $34.01 million for the quarter, compared to analysts' expectations of $32.23 million. SI-BONE had a negative trailing twelve-month return on equity of 32.05% and a negative net margin of 32.98%. What is Jeffrey Dunn's approval rating as SI-BONE's CEO? 10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of SI-BONE own? Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX). When did SI-BONE IPO? (SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are SI-BONE's major shareholders? SI-BONE's stock is owned by a variety of institutional and retail investors. Top institutional investors include Brown Advisory Inc. (10.32%), Morgan Stanley (2.00%), Allspring Global Investments Holdings LLC (1.75%), Wellington Management Group LLP (1.50%), Impax Asset Management Group plc (1.23%) and Paradigm Capital Management Inc. NY (0.96%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky. View institutional ownership trends. How do I buy shares of SI-BONE? Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does SI-BONE have any subsidiaries? The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.Read More This page (NASDAQ:SIBN) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SI-BONE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.